New CTCL Treatment from Soligenix to Begin Phase III Clinical Trial

Biopharmaceutical firm Soligenix has entered into an agreement with the US Food and Drug Administration (FDA) on the design of a major Phase III clinical trial assessing its product SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL).

SGX301 is described as a first-in-class, photodynamic therapy using safe visible light for activation. Its active ingredient, synthetic hypericin, is a potent photosensitizer topically applied to skin lesions and activated by visible fluorescent light.

A double-blind, placebo-controlled Phase II trial in CTCL patients demonstrated the drug's safety and tolerance, with 58.3 percent of the CTCL patients responding to SGX301 treatment compared to only 8.3 percent receiving placebo.

"I have had a lengthy scientific and clinical interest in hypericin and am pleased that the Soligenix team is advancing this product to a Phase 3 clinical study," said Alain Rook director of the Cutaneous Lymphoma Program at the University of Pennsylvania. "I believe that SGX301 has the potential to be a major step forward in the treatment of CTCL by providing a safer alternative therapy over the course of the patients' disease than is currently available."

Based on the positive results showed in the Phase II trial of SGX301,

The Phase III protocol for SGX301 will be a double-blind, randomized, placebo-controlled, multicenter trial enrolling 120 patients.

Source: PBR

More Articles

More Articles

Lymphoma patients may have the option to participate in clinical trials, gaining access to an experimental treatment before it is widely available...

Since there are several subtypes of T cell lymphoma, there will necessarily be several non-specific T cell lymphoma...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

After surviving lymphoma treatments, patients should be on the lookout for late effects. These are symptoms that arise well after treatment has...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...

The short answer: both. Let's begin with a simple definition of radiation: Radiation is the energy emitted from an energy source. That energy...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...